Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.35 |
| ▸ | SGK1 | O00141 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876723 | 0.81 | NOTUM (0.38) | ALDH1A1NPSR1KIF11PTPN5NOTUM | |
| SCHEMBL198143 | 0.75 | NOTUM (0.45) | ALDH1A1NPSR1MAOBRAB9ASMN1; SMN2 | |
| SCHEMBL29280760 | 0.74 | ALDH1A1 (0.41) | ALDH1A1NPSR1DPP4NOTUM | |
| SCHEMBL4246354 | 0.72 | AGTR1 (0.50) | TAAR1CSNK2A1SGK1KIF11CYP2A6 | |
| SCHEMBL16975525 | 0.72 | KIF11 (0.37) | ALDH1A1NPSR1KIF11NPC1RAB9A | |
| SCHEMBL4677210 | 0.71 | TAAR1 (0.39) | TAAR1ALDH1A1CSNK2A1SGK1MAOB | |
| SCHEMBL5362598 | 0.70 | TAAR1 (0.77) | TAAR1ALDH1A1CSNK2A1SGK1MAOB | |
| SCHEMBL3883657 | 0.68 | AGTR1 (0.47) | TAAR1ALDH1A1CSNK2A1SGK1KIF11 | |
| Hydrogen Sulfide SCHEMBL27541593 | 0.68 | TAAR1 (0.74) | TAAR1ALDH1A1CSNK2A1SGK1MAOB | |
| SCHEMBL5633434 | 0.67 | TAAR1 (0.39) | TAAR1CSNK2A1SGK1CD274MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590343-B1 | SYNTHESIS OF 2-BUTYL-3-(2' -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIRO-4,4 -NONENE-4-ONE | TEVA PHARMA (IL) | 2008-07-16 | — | — | EP | claimed |
| US-7312340-B2 | Synthesis of 2-butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-25 | — | — | US | claimed |
| US-20060128967-A1 | Novel synthesis of 2-Butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one | DOLITZKY BEN-ZION | 2006-06-15 | — | — | US | claimed |
| EP-1590343-A1 | SYNTHESIS OF 2-BUTYL-3-(2 -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIROL 4,4 -NON-ENE-4-ONE | Teva Pharmaceutical Industries Limited (IL) | 2005-11-02 | — | — | EP | claimed |
| US-20040242894-A1 | Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | TEVA PHARMACEUTICALS USA, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004072064-A1 | SYNTHESIS OF 2-BUTYL-3-(2'-(1-TRITYL-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)-1,3-DIAZASPIROL[4,4]-NON-ENE-4-ONE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-26 | — | — | WO | claimed |
| EP-2194050-A1 | A new process for the preparation of irbesartan | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2010-06-09 | — | — | EP | disclosed |
| EP-1590343-B1 | SYNTHESIS OF 2-BUTYL-3-(2' -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIRO-4,4 -NONENE-4-ONE | TEVA PHARMA (IL) | 2008-07-16 | — | — | EP | disclosed |
| US-7312340-B2 | Synthesis of 2-butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-25 | — | — | US | disclosed |
| WO-2007052301-A2 | PROCESS FOR THE PREPARATION OF IRBESARTAN | ALEMBIC LIMITED (IN) | 2007-05-10 | — | — | WO | disclosed |
| US-20060128967-A1 | Novel synthesis of 2-Butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one | DOLITZKY BEN-ZION | 2006-06-15 | — | — | US | disclosed |
| US-7038060-B2 | Synthesis of 2-butyl-3-(2′-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-05-02 | — | — | US | disclosed |
| EP-1590343-A1 | SYNTHESIS OF 2-BUTYL-3-(2 -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIROL 4,4 -NON-ENE-4-ONE | Teva Pharmaceutical Industries Limited (IL) | 2005-11-02 | — | — | EP | disclosed |
| US-20040242894-A1 | Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | TEVA PHARMACEUTICALS USA, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004072064-A1 | SYNTHESIS OF 2-BUTYL-3-(2'-(1-TRITYL-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)-1,3-DIAZASPIROL[4,4]-NON-ENE-4-ONE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242894-A1 | Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | AGTR1, AGTR2, TEK | TAAR1 133/4885ALDH1A1 1338/4885NPSR1 236/4885 |
| US-20060128967-A1 | Novel synthesis of 2-Butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one | AGTR1, TEK, AGTR2 | TAAR1 151/4885ALDH1A1 1155/4885NPSR1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.